Korean subsidiaries of multinational pharmaceutical companies have lowered their selling, general & administrative (SG&A) to sales ratio last year due to the prolonged COVID-19 crisis. Analysts predict that the cost-cutting measure was made in response to the disruptions in face-to-face sales and marketing activities caused by the pandemic.

According to the Financial Supervisory Service (FSS) on the 19th, the SG&A expense of 34 major subsidiaries of multinational pharmaceutical companies in Korea last year amounted to 1.7 trillion won, a 0.8% increase from the previous year.

The result is based on audit reports of the 34 subsidiaries that submitted reports to FSS.

3